Jeffrey H Lipton, PhD, MD, FRCPC

I am involved in clinical research at the phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted therapy with kinase inhibitors, drugs that may target the CML stem cell and cells that are resistant to other therapies. The interest in targeted therapy extends into the phase II study of signal transduction inhibitors in the therapy of other diseases such as systemic mastocytosis and mast cell leukemia.

The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.
Haematologica. 2019 Jan 17;:
Zandi S, Kanfar S, Cserti-Gazdewich C, Lipton JH, Pendergrast J
Biol Blood Marrow Transplant. 2019 Jan 14;:
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA
Leukemia. 2018 Dec 16;:
Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH
Leuk Res. 2018 Sep 05;73:67-75
Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDH
Haematologica. 2018 Aug 09;:
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE
Blood Res. 2018 Jun;53(2):172-174
Kavanagh S, Bril V, Lipton JH
Ann Hematol. 2018 Jun 11;:
Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, Deotare U, Michelis FV



Professor of Medicine, University of Toronto